Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin Launches Generic Temovate® Clobetasol Propionate Scalp Application in the US

Mumbai, Baltimore, March 01, 2017: Pharma Major Lupin Limited (Lupin) announced today that it has launched its Clobetasol Propionate Topical Solution USP, 0.05% having received an approval from the United States Food and Drug Administration (FDA) earlier to market a generic version of Fougera Pharmaceuticals' Temovate® (clobetasol propionate) Scalp Application, 0.05%.

Lupin's Clobetasol Propionate Topical Solution USP, 0.05% is an AT rated generic equivalent of Fougera Pharmaceuticals' Temovate® (clobetasol propionate) Scalp Application, 0.05%. It is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.

Temovate® Clobetasol Propionate Scalp Application had US sales of USD 64.1 million (IMS MAT December 2016).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 5th and the 6th largest generics pharmaceutical company by market capitalization (December 31st, 2016, Bloomberg) and sales globally (September 30th, 2016, Bloomberg). The Company is the 5th largest pharmaceutical player in the US by prescriptions (4.68% market share – IMS Health, National Prescription Audit, March 2016); the 2nd largest Indian pharmaceutical company by revenues; the 6th largest generic pharmaceutical player in Japan and the 4th largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31st March, 2016, Lupin's Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter - www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –
Arvind Bothra
Head – Investor Relations and M&A
Ph: +91-70 45 656 895
Email: arvindbothra@lupin.com

*Safe Harbor Statement

Temovate® is the registered trademark of Fougera Pharmaceuticals Inc.